Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | GAA | P10253 | 2/20 | 0.62 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29488200 | 1.00 | HPGD (0.66) | HPGDALDH1A1HTTKMT2AGAA | |
| SCHEMBL31388324 | 0.89 | HPGD (0.80) | HPGDALDH1A1HTTKMT2AGAA | |
| SCHEMBL3822985 | 0.89 | HPGD (0.80) | HPGDALDH1A1HTTKMT2AGAA | |
| SCHEMBL27920292 | 0.86 | HPGD (0.62) | HPGDALDH1A1HTTKMT2AGAA | |
| SCHEMBL13299603 | 0.84 | HPGD (0.68) | HPGDALDH1A1HTTKMT2AGAA | |
| SCHEMBL25347923 | 0.82 | HPGD (0.66) | HPGDALDH1A1HTTKMT2AGAA | |
| SCHEMBL458501 | 0.82 | ALDH1A1 (0.61) | HPGDALDH1A1HTTKMT2AGAA | |
| SCHEMBL1396138 | 0.81 | ALDH1A1 (0.64) | HPGDALDH1A1HTTKMT2AGAA | |
| SCHEMBL29654196 | 0.81 | ALDH1A1 (0.64) | HPGDALDH1A1HTTKMT2AGAA | |
| SCHEMBL17956756 | 0.81 | GAA (0.71) | HPGDALDH1A1HTTKMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115449136-B | Accelerator composition of rubber nanocomposite as well as preparation method and application thereof | 浙江大学 | 2024-02-27 | — | — | CN | claimed |
| CN-115449136-A | Accelerator composition of rubber nanocomposite and preparation method and application thereof | 浙江大学 | 2022-12-09 | — | — | CN | claimed |
| WO-2025046420-A1 | COMPOUND TARGETING EGR-1 AND USE THEREOF FOR TREATMENT OF ATOPIC DERMATITIS | 주식회사 아제라메디 | 2025-03-06 | — | — | WO | disclosed |
| CN-115449136-B | Accelerator composition of rubber nanocomposite as well as preparation method and application thereof | 浙江大学 | 2024-02-27 | — | — | CN | disclosed |
| CN-115449136-A | Accelerator composition of rubber nanocomposite and preparation method and application thereof | 浙江大学 | 2022-12-09 | — | — | CN | disclosed |
| EP-2240175-B1 | COMPOUNDS WITH MDR1-INVERSE ACTIVITY | US GOV HEALTH & HUMAN SERV (US) | 2013-01-02 | — | — | EP | disclosed |
| WO-2012033601-A1 | THIOSEMICARBAZONES WITH MDR1 - INVERSE ACTIVITY | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2012-03-15 | — | — | WO | disclosed |
| US-20100316655-A1 | COMPOUNDS WITH MDR1-INVERSE ACTIVITY | INSTITUTE OF ENZYMOLOGY, BIOLOGICAL RESEARCH CENTER, HUNGARIAN ACADEMY OF SCIENCES (HU) | 2010-12-16 | — | — | US | disclosed |
| EP-2240175-A2 | COMPOUNDS WITH MDR1-INVERSE ACTIVITY | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services (US) | 2010-10-20 | — | — | EP | disclosed |
| WO-2009102433-A2 | COMPOUNDS WITH MDR1-INVERSE ACTIVITY | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2009-08-20 | — | — | WO | disclosed |
| US-20070093483-A1 | Use of derivatives of 2, 4-dihydro-[1,2,4] triazole-3-thione as inhibitors of the enzyme myeloperoxidase (mpo) | ASTRAZENECA AB (SE) | 2007-04-26 | — | — | US | disclosed |
| EP-1620410-A1 | USE OF DERIVATIVES OF 2, 4-DIHYDRO- 1,2,4 TRIAZOLE-3-THIONE AS INHIBITORS OF THE ENZYME MYELOPEROXIDASE (MPO) | AstraZeneca AB (SE) | 2006-02-01 | — | — | EP | disclosed |
| WO-2004096781-A1 | USE OF DERIVATIVES OF 2, 4-DIHYDRO-[1,2,4]TRIAZOLE-3-THIONE AS INHIBITORS O FTEH ENZYME MYELOPEROXIDASE (MPO) | ASTRAZENECA AB (SE) | 2004-11-11 | — | — | WO | disclosed |
| US-4871737-A | 3-Amino-5-methyl-1H-pyrazole-4-carboxylic acids and esters thereof as anticonvulsants muscle relaxants and anxiolytics | A. H. ROBINS COMPANY, INCORPORATED (US) | 1989-10-03 | — | — | US | disclosed |
| EP-0315433-A2 | 3-amino-5-methyl-1H-pyrazole-4-carboxylic acids and esters thereof as anticonvulsants, muscle relaxants and anxiolytics | A.H. ROBINS COMPANY, INCORPORATED (US) | 1989-05-10 | — | — | EP | disclosed |
| US-4826866-A | 3-amino-5-methyl-1H-pyrazole-4-carboxylic acids and esters thereof as anticonvulsants, muscle relaxants and anxiolytics | A. H. ROBINS COMPANY, INCORPORATED (US) | 1989-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100316655-A1 | COMPOUNDS WITH MDR1-INVERSE ACTIVITY | ABCC1, ABCB1, ABCC2 | HPGD 1986/4885ALDH1A1 1607/4885HTT 2897/4885 |
| US-20070093483-A1 | Use of derivatives of 2, 4-dihydro-[1,2,4] triazole-3-thione as inhibitors of the enzyme myeloperoxidase (mpo) | MPO, XDH, EPX | HPGD 114/4885ALDH1A1 151/4885HTT 1667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.